Difficulty: Medium
Average Score: 68%
Practice
A 70-year-old man has severe urinary hesitancy associated with benign prostatic hyperplasia. He has tried alpha blockers with little relief. His physician recommends a drug that blocks 5╬▒ reductase in the prostate and writes a prescription for
Correct answer
D
Rationale
The correct answer is D) None of the above. In this scenario, the physician is recommending a drug that blocks 5╬▒ reductase in the prostate to address the urinary hesitancy associated with benign prostatic hyperplasia. This drug is likely referring to finasteride or dutasteride, which are 5╬▒ reductase inhibitors commonly used in the treatment of BPH.
Option A) Atropine is a muscarinic antagonist used for conditions like bradycardia or to reduce salivary and bronchial secretions, not for BPH.
Option B) Clonidine is an alpha-2 adrenergic agonist primarily used for hypertension or ADHD, not for BPH.
Option C) Hydralazine is a direct-acting vasodilator used for hypertension, not for BPH.
Understanding the mechanism of action of drugs used in the treatment of BPH is crucial for healthcare professionals to make appropriate prescribing decisions. This question assesses the knowledge of students on the pharmacological management of BPH and the specific drug classes used to address urinary symptoms in this condition. It highlights the importance of tailoring treatment to the underlying pathophysiology of the patient's condition for optimal outcomes.
Option A) Atropine is a muscarinic antagonist used for conditions like bradycardia or to reduce salivary and bronchial secretions, not for BPH.
Option B) Clonidine is an alpha-2 adrenergic agonist primarily used for hypertension or ADHD, not for BPH.
Option C) Hydralazine is a direct-acting vasodilator used for hypertension, not for BPH.
Understanding the mechanism of action of drugs used in the treatment of BPH is crucial for healthcare professionals to make appropriate prescribing decisions. This question assesses the knowledge of students on the pharmacological management of BPH and the specific drug classes used to address urinary symptoms in this condition. It highlights the importance of tailoring treatment to the underlying pathophysiology of the patient's condition for optimal outcomes.